Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education
Part of paid clinical trials in Seattle, Washington.
- Sponsor
- Fred Hutchinson Cancer Center
- Study ID
- NCT06995924
- Status
- Recruiting
Conditions
- Stage I Colorectal Cancer AJCC v8
- Stage II Colorectal Cancer AJCC v8
- Stage III Colorectal Cancer AJCC v8
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Educational Intervention — OTHERComplete self-directed interactive education
- Electronic Health Record Review — OTHERAncillary studies
- Internet-Based Intervention — OTHERReceive access to CTAC
- Patient Navigation — BEHAVIORALReceive patient navigation services
- Survey Administration — OTHERAncillary studies
Study Details
This pilot clinical trial looks at whether patient navigation services, an interactive web education intervention, called Current Together After Cancer (CTAC), or both navigation and CTAC works to improve the uptake of surveillance in patients with stage I-III colorectal cancer (CRC). Post-treatment surveillance is critical to detect recurrence early, yet many CRC survivors do not receive recommended surveillance care. Surveillance is a complex process that includes laboratory tests, cross-sectional imaging, and endoscopic procedures. Patient navigation services, interactive web education, or a combination of both may improve surveillance care for patients with stage I-III colorectal cancer.
Key Dates
- Start date
- Nov 17, 2025
- Status verified
- Feb 2026
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 75 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Arm A (navigation)Patients at the Virginia Mason clinic location receive access to navigation services, in person, via telephone or via electronic conferencing platform, including education on surveillance care, reminders to complete care and assistance in scheduling surveillance, within 3 months of standard of care surgical resection.
- Experimental: Arm B (CTAC)Patients at the Fred Hutch (South Lake Union) clinic location receive access to the online CTAC intervention, which includes self-directed, interactive education about surveillance and a checklist of care, within 3 months of standard of care surgical resection.
- Experimental: Arm C (navigation and CTAC)Patients at the Fred Hutch (Overlake + Evergreen) clinic location receive access to navigation services, in person, via telephone or via electronic conferencing platform, including education on surveillance care, reminders to complete care and assistance in scheduling surveillance, and access to the online CTAC intervention, which includes self-directed, interactive education about surveillance and a checklist of care, within 3 months of standard of care surgical resection.
Primary Outcome Measure
Completion of colonoscopy (stage I colorectal carcinoma patients) [ Time Frame: Up to 18 months post-surgical resection ]
Central Contacts
- Ari Bell-Brown206.667.7624
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Benaroya Research Institute at Virginia Mason | Seattle | Washington | 98101 | Vlad Simianu, MD, MPH, FACS, FASCRS (PRINCIPAL_INVESTIGATOR) |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | Rachel B. Issaka, MD, MAS (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Seattle, WA
Related Studies
- Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer SurvivorsRecruiting · Fred Hutchinson Cancer Center · Seattle, Washington
- Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal CancerPHASE1 · Recruiting · Roswell Park Cancer Institute · Buffalo, New York
- Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C StudyRecruiting · M.D. Anderson Cancer Center · Gilbert, Arizona
- Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and EffectivenessPHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Irvine, California